Literature DB >> 20722746

Haemophilia care in Europe: a survey of 19 countries.

B O'Mahony1, D Noone, P L F Giangrande, L Prihodova.   

Abstract

In 2009, a questionnaire was circulated to 19 national haemophilia patient organizations in Europe affiliated to the European Haemophilia Consortium (EHC) and the World Federation of Hemophilia (WFH) to seek information about the organization of haemophilia care and treatment available at a national level. The responses received highlighted differences in the level of care despite the recent promulgation of consensus guidelines designed to standardize the care of haemophilia throughout the continent of Europe. There was a wide range in factor VIII consumption with usage ranging from 0.38 IU per capita in Romania to 8.7 IU per capita in Sweden (median: 3.6 IU per capita). Despite the specific inclusion of coagulation factor concentrate in the WHO list of essential medications, cryoprecipitate is still used in some eastern European countries.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20722746     DOI: 10.1111/j.1365-2516.2010.02362.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  7 in total

1.  Tailoring care to haemophilia patients' needs: which specialty and when?

Authors:  Massimo Morfini; Gary Benson; Victor Jiménez-Yuste; Rolf Ljung; Pier Mannuccio Mannucci; Gianluigi Pasta; Eduardo Remor; Silva Zupančić Šalek
Journal:  Blood Transfus       Date:  2015-05-20       Impact factor: 3.443

2.  Social/economic costs and quality of life in patients with haemophilia in Europe.

Authors:  Marianna Cavazza; Yllka Kodra; Patrizio Armeni; Marta De Santis; Julio López-Bastida; Renata Linertová; Juan Oliva-Moreno; Pedro Serrano-Aguilar; Manuel Posada-de-la-Paz; Domenica Taruscio; Arrigo Schieppati; Georgi Iskrov; László Gulácsi; Johann Matthias Graf von der Schulenburg; Panos Kanavos; Karine Chevreul; Ulf Persson; Giovanni Fattore
Journal:  Eur J Health Econ       Date:  2016-04-05

3.  Issues in assessing products for the treatment of hemophilia - the intersection between efficacy, economics, and ethics.

Authors:  Albert Farrugia; Declan Noone; Uwe Schlenkrich; Steffen Schlenkrich; Brian O'Mahony; Josephine Cassar
Journal:  J Blood Med       Date:  2015-06-15

4.  Evolution of Haemophilia Care in Europe: 10 years of the principles of care.

Authors:  D Noone; B O'Mahony; F Peyvandi; M Makris; A Bok
Journal:  Orphanet J Rare Dis       Date:  2020-07-13       Impact factor: 4.123

5.  The impact of improving haemophilia A management within the Spanish National Healthcare System: a social return on investment analysis.

Authors:  Inmaculada Soto; José Mateo; Daniel-Aníbal García-Diego; Beatriz Gil; Elena Ruiz-Beato; Yoana Ivanova; Teresa Martín Lorenzo; Paulina Maravilla-Herrera; Álvaro Hidalgo-Vega; María Merino
Journal:  BMC Health Serv Res       Date:  2022-01-26       Impact factor: 2.655

6.  Multiple criteria decision analysis for therapeutic innovations in a hemophilia care center: A pilot study of the organizational impact of innovation in hemophilia care management.

Authors:  Karen Beny; Amélie Dubromel; Benjamin du Sartz de Vigneulles; Valérie Gay; Florence Carrouel; Claude Negrier; Claude Dussart
Journal:  PLoS One       Date:  2022-09-09       Impact factor: 3.752

7.  Haemophilia in France: Modelisation of the Clinical Pathway for Patients.

Authors:  Karen Beny; Benjamin du Sartz de Vigneulles; Florence Carrouel; Denis Bourgeois; Valérie Gay; Claude Negrier; Claude Dussart
Journal:  Int J Environ Res Public Health       Date:  2022-01-06       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.